Recently, according to the official website of Beckman Coulter Life Sciences, a subsidiary of Danaher, Beckman Coulter Life Sciences announced the appointment of Joe Fox as President, effective immediately.

Following the promotion of Chen Xiaoxiao, former General Manager of Beckman Clinical Diagnostics China, to President of Danaher China Medical Diagnostic Platform in the first half of the year, Beckman has once again announced personnel changes.

It is understood that Joe Fox is a veteran of Danaher and has served as the president of Danaher's subsidiary, Sciex. Prior to becoming president, he held multiple leadership positions at the company, including Senior Vice President of Global Sales and Service. Over the course of 13 years, Joe Fox's responsibilities have increased, until he recently became president.

Prior to joining Sciex, Joe Fox held technical and business positions at Bruker and Shimadzu, and also holds a Bachelor of Science degree in Biochemistry from the University of Delaware and a Ph.D. in Chemistry from Johns Hopkins University.

After taking office, Joe Fox will lead a global team of over 3300 employees, driving product and service innovation to provide solutions in areas such as workflow centrifugation, flow cytometry, genomics, particle analysis, and liquid handling. In addition, Joe Fox will also support Beckman's commitment to sustainability, including further integrating sustainability into operations, products, and packaging.

Beckman was founded in 1935 with the invention of a pH meter by Dr. Beckman, which can be used to accurately measure the pH value of lemon juice. From a small business located in a car repair shop in Pasadena, California, to a global giant in clinical diagnostics and life sciences, Beckman's success is mainly attributed to three visionary scientists: Dr. Beckman and the Kurt brothers, who brought significant changes to technology and medicine. In 1997, Beckman and Coulter merged to become Beckman Coulter Limited today. In 2011, Danaher acquired Beckman at a high price of $6.8 billion.

Since the beginning of this year, Danaher has also sent out many personnel change messages, with 5 personnel changes in the first half of the year alone:
 Chen Xiaoxiao, General Manager of Beckman Clinical Diagnostics China, has been promoted to President of China Diagnostic Platform;
 Li Lei, President of Danaher China Life Science Platform, has been promoted to the new President of SITOFAN China;
 Zhou Mintao, former President of Danaher China Biotechnology Platform and President of SITOFAN China, announced his resignation;
 Kevin O'Reilly replaces Julie Sawyer Montgomery as the new president of Beckman Diagnostics, while also serving as the vice president and group executive of Danaher Medical Diagnostics business unit;
 Danaher board member Walter Lohr announced his retirement from the board in May of this year.

Regarding the appointment of Joe Fox, Vice President Greg Milosevich and Group Executive of Danaher Life Sciences Innovation Group, Vice President of the Inclusion and Dedication Team for the Life Sciences and Clinical Industries, stated that Joe is a recognized leader with a track record of successful business development and building diversity. Joe has a unique understanding of Danaher's strategy, the culture of Danaher Business Systems (DBS), and a strong commitment to excellent customers. Joe will help Beckman cultivate and attract top clients while continuing to provide meaningful innovative talent.

Beckman's development momentum is rapid
Since its establishment, Beckman has developed rapidly. In the past century, various instruments under the "Beckman" and "Kurt" brands have been widely recognized and accepted by medical personnel and researchers around the world. Beckman's main products include flow cytometry, clinical flow cytometry, centrifuges, automated liquid workstations, genomics, synthetic biology, cell health analysis, particle quality control tools, after-sales service, etc. Its products are mainly used in cutting-edge and important research fields, including genomics, proteomics, proteomics, and biopharmaceuticals.

In recent years, Beckman's development momentum has continued to grow, and this growth momentum is also reflected in Danaher's financial report.

On March 29, 2024, Danaher Group announced its quarterly results. In the first quarter, Danaher's total revenue was $5.8 billion, with diagnostic revenue of $2.527 billion, accounting for 43.5%. The core sales of the diagnostic business increased by 7.5%, achieving growth for five consecutive quarters. Beckman achieved single digit growth, mainly due to the recently launched DxI900, DxC500, and DxA5000 products.

It is reported that Beckman has launched several new solutions in 2024 to improve laboratory workflows, including the CytoFLEX nanoflow cytometer, which completely changes nanoparticle analysis. The QbD1200+total organic carbon analyzer can accelerate pharmaceutical and biopharmaceutical analysis, and the Biomek Echo One system can prepare high-throughput genomic samples. The company has recently partnered with DLL Financial Solutions, a wholly-owned subsidiary of Rabobank, to make financing options easier to obtain.

Source: https://news.yaozh.com/archive/44327.html